Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.9
4.9
Journals
Pharmaceutics
Special Issues
Novel Natural Pharmaceutics with Action on Buccal Diseases Such as...
share announcement

Novel Natural Pharmaceutics with Action on Buccal Diseases Such as Caries, Periodontal Disease, and Fungi Infections

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".

Deadline for manuscript submissions: closed (30 October 2022) | Viewed by 9294

Special Issue Editor

Dr. Bruno Bueno-Silva

E-Mail Website
Guest Editor
Dental Research Division, Guarulhos University, São Paulo 07023-070, Brazil
Interests: antimicrobial; nutraceutical; complementary and alternative medicine; inflammation; propolis

Special Issue Information

Dear Colleagues,

Natural products have emerged as a relevant source of novel molecules with pharmaceutical properties. Of these properties, the antimicrobial and anti-inflammatory activities stand out. Both are relevant to the principal diseases in the dental field: caries and periodontitis. Dental caries is a biofilm-mediated, diet-modulated, multifactorial, dynamic disease resulting in net mineral loss of dental hard tissues. Periodontitis is an inflammatory dysbiotic pathology that affects the supporting tissues of teeth, including the gums, periodontal ligament, and alveolar bone. This disease has a complex etiology, including microbial communities capable of bypassing the host immune system and an exacerbated inflammatory reaction, which produces tissue destruction and even loss of function of the dental element. Therefore, inflammatory mediators and the periodontopathogenic biofilm play a fundamental role in the etiology and development of periodontitis. In this sense, the search for new compounds that can modulate the host immunoinflammatory response and antimicrobial activity is a novel and relevant research field.

This Special Issue serves to highlight and capture results related to the outstanding natural pharmaceutics that are being developed. We invite articles describing the antimicrobial and anti-inflammatory effects of natural products. The effect of natural pharmaceutics on these matters and also related to oral disease are very welcome.

Dr. Bruno Bueno-Silva
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • natural products
  • anti-inflammatory
  • antimicrobial
  • pharmaceuticals
  • dentistry

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 1258 KiB  
Article
A Study on the Anti-NF-κB, Anti-Candida, and Antioxidant Activities of Two Natural Plant Hormones: Gibberellin A4 and A7
by Bruno Dias Nani, Pedro Luiz Rosalen, Josy Goldoni Lazarini, Janaína de Cássia Orlandi Sardi, Diego Romário-Silva, Leonardo Pereira de Araújo, Mateus Silva Beker dos Reis, Isadora Breseghello, Thiago Mattar Cunha, Severino Matias de Alencar, Nelson José Freitas da Silveira and Marcelo Franchin
Pharmaceutics 2022, 14(7), 1347; https://doi.org/10.3390/pharmaceutics14071347 - 25 Jun 2022
Cited by 8 | Viewed by 2374
Abstract
Introduction: Gibberellins (GA) are terpenoids that serve as important plant hormones by acting as growth and response modulators against injuries and parasitism. In this study, we investigated the in vitro anti-NF-κB, anti-Candida, and antioxidant activity of gibberellin A4 (GA4) and A7 [...] Read more.
Introduction: Gibberellins (GA) are terpenoids that serve as important plant hormones by acting as growth and response modulators against injuries and parasitism. In this study, we investigated the in vitro anti-NF-κB, anti-Candida, and antioxidant activity of gibberellin A4 (GA4) and A7 (GA7) compounds, and further determined their toxicity in vivo. Methods: GA4 and GA7 in vitro toxicity was determined by MTT method, and nontoxic concentrations were then tested to evaluate the GA4 and GA7 anti-NF-κB activity in LPS-activated RAW-luc macrophage cell culture (luminescence assay). GA4 in silico anti-NF-κB activity was evaluated by molecular docking with the software “AutoDock Vina”, “MGLTools”, “Pymol”, and “LigPlot+”, based on data obtained from “The Uniprot database”, “Protein Data Bank”, and “PubChem database”. The GA4 and GA7 in vitro anti-Candida effects against Candida albicans (MYA 2876) were determined (MIC and MFC). GA7 was also evaluated regarding the viability of C. albicans preformed biofilm (microplate assay). In vitro antioxidant activity of GA4 and GA7 was evaluated against peroxyl radicals, superoxide anions, hypochlorous acid, and reactive nitrogen species. GA4 and GA7 in vivo toxicity was determined on the invertebrate Galleria mellonella larvae model. Results: Our data show that GA4 at 30 µM is nontoxic and capable of reducing 32% of the NF-κB activation on RAW-luc macrophages in vitro. In vitro results were confirmed via molecular docking assay (in silico), since GA4 presented binding affinity to NF-κB p65 and p50 subunits. GA7 did not present anti-NF-κB effects, but exhibited anti-Candida activity with low MIC (94 mM) and MFC (188 mM) values. GA7 also presented antibiofilm properties at 940 mM concentration. GA4 did not present anti-Candida effects. Moreover, GA4 and GA7 showed antioxidant activity against peroxyl radicals, but did not show scavenging activity against the other tested radicals. Both compounds did not affect the survival of G. mellonella larvae, even at extremely high doses (10 g/Kg). Conclusion: Our study provides preclinical evidence indicating that GA4 and GA7 have a favorable low toxicity profile. The study also points to GA4 and GA7 interference with the NF-κB via, anti-Candida activity, and a peroxyl radical scavenger, which we argue are relevant biological effects. Full article
(This article belongs to the Special Issue Novel Natural Pharmaceutics with Action on Buccal Diseases Such as Caries, Periodontal Disease, and Fungi Infections)
►▼ Show Figures

Figure 1

Review

Jump to: Research

17 pages, 3540 KiB  
Review
The Use of Probiotics as Adjuvant Therapy of Periodontal Treatment: A Systematic Review and Meta-Analysis of Clinical Trials
by Louis Hardan, Rim Bourgi, Carlos Enrique Cuevas-Suárez, Maythé Flores-Rodríguez, Arianna Omaña-Covarrubias, Marco Nicastro, Florin Lazarescu, Maciej Zarow, Paulo Monteiro, Natalia Jakubowicz, Patrycja Proc and Monika Lukomska-Szymanska
Pharmaceutics 2022, 14(5), 1017; https://doi.org/10.3390/pharmaceutics14051017 - 9 May 2022
Cited by 22 | Viewed by 6299
Abstract
For many years, the use of probiotics in periodontitis treatment was reflected in their abilities to control the immune response of the host to the presence of pathogenic microorganisms and to upset periodontopathogens. Accordingly, the aim of the present study was to assess [...] Read more.
For many years, the use of probiotics in periodontitis treatment was reflected in their abilities to control the immune response of the host to the presence of pathogenic microorganisms and to upset periodontopathogens. Accordingly, the aim of the present study was to assess the use of probiotics as adjuvant therapy on clinical periodontal parameters throughout a systematic review and meta-analysis. The literature was screened, up to 4 June 2021, by two independent reviewers (L.H. and R.B.) in four electronic databases: PubMed (MedLine), ISI Web of Science, Scielo, and Scopus. Only clinical trials that report the effect of the use of probiotics as adjuvants in the treatment of periodontal disease were included. Comparisons were carried out using Review Manager Software version 5.3.5 (The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen, Denmark). A total of 21 studies were considered for the meta-analysis. For the index plaque, the use of probiotics did not improve this clinical parameter (p = 0.16). On the other hand, for the periodontal pocket depth, the clinical attachment loss, the bleeding on probing, and the use of probiotics as adjuvant therapy resulted in an improvement of these parameters, since the control group achieved statistically higher values of this parameter (p < 0.001; p < 0.001; and p = 0.005, respectively). This study suggests that the use of probiotics led to an improvement in periodontal pocket depth, clinical attachment loss, and bleeding on probing parameters. On the other hand, this protocol seems to not be beneficial for the index plaque parameter. Full article
(This article belongs to the Special Issue Novel Natural Pharmaceutics with Action on Buccal Diseases Such as Caries, Periodontal Disease, and Fungi Infections)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop